Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Debt (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Total Debt over the past 15 years, most recently at $121.2 million for Q2 2025.

  • Quarterly results put Total Debt at $121.2 million for Q2 2025, up 19.3% from a year ago — trailing twelve months through May 2025 was $121.2 million (up 19.3% YoY), and the annual figure for FY2025 was $121.2 million, up 19.3%.
  • Total Debt for Q2 2025 was $121.2 million at Lifecore Biomedical, Inc. \De\, up from $115.7 million in the prior quarter.
  • Over the last five years, Total Debt for LFCR hit a ceiling of $193.9 million in Q2 2021 and a floor of $9.3 million in Q4 2024.
  • Median Total Debt over the past 5 years was $97.6 million (2022), compared with a mean of $89.9 million.
  • Biggest five-year swings in Total Debt: tumbled 86.61% in 2023 and later surged 506.93% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Total Debt stood at $166.2 million in 2021, then plummeted by 71.12% to $48.0 million in 2022, then crashed by 63.23% to $17.7 million in 2023, then tumbled by 47.46% to $9.3 million in 2024, then surged by 1207.0% to $121.2 million in 2025.
  • The last three reported values for Total Debt were $121.2 million (Q2 2025), $115.7 million (Q1 2025), and $9.3 million (Q4 2024) per Business Quant data.